CD8A and neoplasm: Taken together, these results suggested that, regardless of whether the tumour models responded to PD1 blockade, TNFR2 blockade could suppress tumour growth and enhance the therapeutic effect of anti-PD1 treatment by boosting the functions of cytotoxic CD8+ T cells and reducing the infiltration, not proliferation, of CCR8+ Tregs.